Co-founder Namgoo Song of MEDIAIPLUS receives the Excellence Award at the SME AI Transformation Best Practices Contest held in Changwon | Photo by MEDIAIPLUS
AI-based clinical trial innovation company MEDIAIPLUS(CEO JiHee Jung) won the Excellence Award at the ‘SME AI Transformation Best Practices Contest’ held on the 19th at the Changwon Convention Center. The contest targeted small and medium-sized enterprises (SMEs) and small business owners who have achieved real results through AI adoption. MEDIAIPLUS was recognized for its contribution to digital innovation in the healthcare industry and for strengthening global competitiveness.
MEDIAIPLUS accelerates innovation in clinical trials with its clinical trial data platform MediC and its AI-based CRO matching platform FiCRO, supporting everything from clinical trial design to partner matching. These technologies play a vital role in improving the speed and accessibility of new drug and medical device development while enhancing the reliability and efficiency of the medical research ecosystem.
The ‘SME AI Transformation Best Practices Contest’ was established to promote the use of AI across industries and to identify outstanding SMEs that have achieved tangible business outcomes. This award is recognized as a case showing that AI can create both productivity and public value even in highly specialized industries such as healthcare.
MEDIAIPLUS’s achievement demonstrates that AI can simultaneously generate tangible productivity and social value in the healthcare sector. By leveraging extensive clinical trial data, the company has shortened clinical trial preparation time and presented a global AI healthcare model led by SMEs through domestic and international collaboration networks, earning high praise.
CEO JiHee Jung of MEDIAIPLUS said, “It is meaningful that the innovation of our AI solutions, which have been leading the digital transformation of the pharmaceutical and healthcare industries, has been recognized,” adding, “We will continue to play a central role in transforming the global clinical trial ecosystem through constant research and development.”
